Cervical microbiota diversity and functional shifts in the development of cervical high-grade squamous intraepithelial lesions
Research on microbial changes in the cervix, where most human papillomavirus (HPV) complications arise, is limited. Here, we aimed to understand the specific role of the cervicovaginal microbiota in developing high-grade squamous intraepithelial lesions (HSIL) associated with HPV infection. Our results show higher diversity in the microbiota associated with HSIL, with the genera <i>Parvimonas, Fastidiosipila</i>, and <i>Pseudomonas</i> being the most abundant. Additionally, an imputed functional analysis revealed that pathways such as glycine, serine, threonine, and sulfur metabolism were enriched in cervical samples from women with HSIL. Identifying biomarkers that help prevent HSIL progression could benefit women at risk of developing HPV-related cancerous lesions.
Authors
- Matilde Sánchez‐Conde (ORCID: https://orcid.org/0000-0003-3880-199X)
- Marta Rosas Cancio-Suárez (ORCID: https://orcid.org/0000-0001-7113-2471)
- Laura Luna Figueroa (ORCID: https://orcid.org/0000-0002-7863-4543)
- Sergio Serrano‐Villar (ORCID: https://orcid.org/0000-0002-5447-3554)
- M.D. Salvador (ORCID: https://orcid.org/0000-0002-4242-478X)
- Carlos Tapia (ORCID: https://orcid.org/0000-0002-0075-4668)
- C. Vanesa Díaz-García (ORCID: https://orcid.org/0000-0001-7570-7113)
- Santiago Moreno (ORCID: https://orcid.org/0000-0002-2843-1094)
- Elena Moreno (ORCID: https://orcid.org/0000-0002-7266-0791)
- Ana Zaida Gómez Moreno
- Cristina del Valle Rubido
- Ana del Amo
Institutions
- Universidad de Alcalá (ES)
- Instituto de Salud Carlos III (ES)
- Universidad Nebrija (ES)
- Madrid Health Service (ES)
- Fundación Andrés Marcio (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fmed.2025.1615571
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- Instituto de Salud Carlos III
- European Regional Development Fund
- European and Developing Countries Clinical Trials Partnership